Skip to main content

Advertisement

SpringerLink
Log in

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Cytogenetic analyses of chronic myelogenous leukemia (CML) have been performed previously in a large number of reports, but systematical research based on large sample sizes from the Chinese population is seldom available. In this study, we analyzed the cytogenetic profiles of 1,863 Philadelphia (Ph)/BCR-ABL-positive CML patients from a research center in China. Of 1,266 newly diagnosed CML patients, the median age was 41 years, which is younger than the median age of diagnosis in western populations. The incidence of additional chromosome abnormalities (ACA) was 3.1% in newly diagnosed chronic phase (CP), 9.1% in CP after therapy, 35.4% in accelerated phase, and 52.9% in blast crisis (BC), reflecting cytogenetic evolution with CML progression. A higher prevalence of ACA was observed in variant Ph translocations than in standard t(9;22) in the disease progression, especially in BC (88.2% vs. 50%, P = 0.002). Moreover, a hyperdiploid karyotype and trisomy 8 were closely correlated with myeloid BC, while a hypodiploid karyotype and monosomy 7 were associated with lymphoid-BC. Among subsets of myeloid-BC, myeloid-BC with minimal differentiation had a higher ACA rate than myeloid-BC with granulocytic differentiation (80% vs. 46.8%, P = 0.009) and myeloid-BC with monocytic differentiation (80% vs. 42.9%, P = 0.006). These data provide novel insights into cytogenetics of CML within the Chinese population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Quintas-Cardama A, Cortes JE (2006) Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 81:973–988

    Article  CAS  PubMed  Google Scholar 

  2. Benneriah Y, Daley GQ, Mesmasson AM, Witte ON, Baltimore D (1986) The chronic myelogenous leukemia specific P210-protein is the product of the Bcr/Abl hybrid gene. Science 233:212–214

    Article  CAS  Google Scholar 

  3. Voncken JW, Kaartinen V, Pattengale PK, Germeraad WTV, Groffen J, Heisterkamp N (1995) Bcr/Abl P210 and P190 cause distinct leukemia in transgenic mice. Blood 86:4603–4611

    Article  CAS  PubMed  Google Scholar 

  4. Calabretta B, Perrotti D (2004) The biology of CML blast crisis. Blood 103:4010–4022

    Article  CAS  PubMed  Google Scholar 

  5. Ch'ang HJ, Tien HF, Wang CH et al (1993) Comparison of clinical and biologic features between myeloid and lymphoid transformation of Philadelphia chromosome positive chronic myeloid leukemia. Cancer Genet Cytogenet 71:87–93

    Article  CAS  PubMed  Google Scholar 

  6. Krulik M, Smadja N, Degramont A et al (1987) Sequential karyotype study on Ph-positive chronic myelocytic-leukemia—significance of additional chromosomal-abnormalities during disease evolution. Cancer 60:974–979

    Article  CAS  PubMed  Google Scholar 

  7. Michalova K, Musilova J, Koudelova Z, Placerova J, Matuchova L (1988) Cytogenetic study of chronic myeloid leukemia. Neoplasma 35:571–581

    CAS  PubMed  Google Scholar 

  8. Reid AG, De Melo VA, Elderfield K et al (2009) Phenotype of blasts in chronic myeloid leukemia in blastic phase-analysis of bone marrow trephine biopsies and correlation with cytogenetics. Leuk Res 33:418–425

    Article  PubMed  Google Scholar 

  9. Parreira L, Kearney L, Rassool F et al (1986) Correlation between chromosomal-abnormalities and blast phenotype in the blast crisis of Ph-positive Cgl. Cancer Genet Cytogenet 22:29–34

    Article  CAS  PubMed  Google Scholar 

  10. Lippert E, Etienne G, Mozziconacci MJ et al (2010) Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy. Haematologica 95:1604–1607

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cheng Y, Wang Y, Wang H et al (2009) Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China. Leukemia 23:1801–1806

    Article  CAS  PubMed  Google Scholar 

  12. Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497

    Google Scholar 

  13. Rowley JD (1973) New consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293

    Article  CAS  PubMed  Google Scholar 

  14. Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 22:295–302

    Article  PubMed  Google Scholar 

  15. Rohrbacher M, Berger U, Hochhaus A et al (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23:602–604

    Article  CAS  PubMed  Google Scholar 

  16. Tardieu S, Brun-Strang C, Berthaud P et al (2005) Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. Pharmacoepidemiol Drug Saf 14:545–553

    Article  PubMed  Google Scholar 

  17. Au WY, Caguioa PB, Chuah C et al (2009) Chronic myeloid leukemia in Asia. Int J Hematol 89:14–23

    Article  PubMed  Google Scholar 

  18. Weng HH, Tsai SS, Chiu HF, Wu TN, Yang CY (2008) Association of childhood leukemia with residential exposure to petrochemical air pollution in Taiwan. Inhal Toxico 2:31–36

    Article  CAS  Google Scholar 

  19. Yu CL, Wang SF, Pan PC et al (2009) Residential exposure to petrochemicals and the risk of leukemia: using geographic information system tools to estimate individual-level residential exposure. Am J Epidemiol 164:200–207

    Article  Google Scholar 

  20. Wong CM, Vichit-Vadakan N, Kan H, Qian Z (2008) Public Health and Air Pollution in Asia (PAPA): a multicity study of short-term effects of air pollution on mortality. Environ Health Perspect 116:1195–1202

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Bennour A, Sennana H, Laatiri MA, Elloumi M, Khelif A, Saad A (2009) Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9. Cancer Genet Cytogenet 194:30–37

    Article  CAS  PubMed  Google Scholar 

  22. Lowenberg B, Hagemeijer A, Abels J (1985) Detection of the blastic crisis cell clone in chronic myeloid-leukemia. Br J Haematol 59:27–36

    Article  CAS  PubMed  Google Scholar 

  23. Mitelman F (1993) The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 11(Suppl 1):11–15

    Article  PubMed  Google Scholar 

  24. Kantarjian HM, Keating MJ, Talpaz M et al (1987) Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 83:445–454

    Article  CAS  PubMed  Google Scholar 

  25. Quintas-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619–1630

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D (2006) t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer 106:1730–1738

    Article  CAS  PubMed  Google Scholar 

  27. Johansson B, Fioretos T, Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76–94

    Article  CAS  PubMed  Google Scholar 

  28. Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM (1996) Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 14:196–203

    Article  CAS  PubMed  Google Scholar 

  29. O'Dwyer ME, Mauro MJ, Kurilik G et al (2002) The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100:1628–1633

    Article  CAS  PubMed  Google Scholar 

  30. O'Dwyer ME, Mauro MJ, Blasdel C et al (2004) Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 103:451–455

    Article  CAS  PubMed  Google Scholar 

  31. Verma D, Kantarjian H, Shan J et al (2010) Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 116:2673–2681

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Fabarius A, Leitner A, Hochhaus A et al (2010) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML study IV. Blood 118:6760–6768

    Article  CAS  Google Scholar 

  33. El-Zimaity MM, Kantarjian H, Talpaz M et al (2004) Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 125:187–195

    Article  CAS  PubMed  Google Scholar 

  34. Gorusu M, Benn P, Li ZH, Fang M (2007) On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet 173:97–106

    Article  CAS  PubMed  Google Scholar 

  35. Sinclair PB, Nacheva EP, Leversha M et al (2000) Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95:738–743

    Article  CAS  PubMed  Google Scholar 

  36. Huntly BJ, Reid AG, Bench AJ et al (2001) Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98:1732–1738

    Article  CAS  PubMed  Google Scholar 

  37. Marzocchi G, Castagnetti F, Luatti S et al (2011) Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA WP on CML analysis. Blood 117:6793–6800

    Article  CAS  PubMed  Google Scholar 

  38. Diezmartin JL, Dewald GW, Pierre RV (1988) Possible cytogenetic distinction between lymphoid and myeloid blast crisis in chronic granulocytic-leukemia. Am J Hematol 27:194–203

    Article  CAS  Google Scholar 

  39. Nacheva EP, Brazma D, Virgili A et al (2010) Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia. Bmc Genomics 11:41

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T (2005) Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. Ann Hematol 84:785–791

    Article  PubMed  Google Scholar 

  41. Bene MC, Bernier M, Casasnovas RO et al (2001) Acute myeloid leukaemia MO: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol 113:737–745

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Mr. Colles Price from the University of Chicago Medical Center, Chicago, IL, USA, for grammatical and cosmetic polishing in English writing.

Author's contributions

Qitian Mu designed the research, collected and analyzed data, and wrote the manuscript. Qiuling Ma collected and analyzed data. Yungui Wang, Zhimei Chen, Xiangmin Tong, Fei-Fei Chen, and Ying Lu collected data and performed research. Jie Jin designed the research and reviewed the manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310003, Zhejiang, People’s Republic of China

    Qitian Mu, Qiuling Ma, Yungui Wang, Zhimei Chen, Xiangmin Tong, Fei-Fei Chen & Jie Jin

  2. Ningbo First Hospital, Ningbo, 315010, Zhejiang, People’s Republic of China

    Qitian Mu & Ying Lu

  3. Department of Hematology, The Second Affiliated Hospital of Henan College of Traditional Chinese Medicine, No. 6 Dongfeng Road, Zhengzhou, 450002, Henan, People’s Republic of China

    Qiuling Ma

Authors
  1. Qitian Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiuling Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yungui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhimei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiangmin Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fei-Fei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ying Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jie Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jie Jin.

Additional information

Qitian Mu and Qiuling Ma contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mu, Q., Ma, Q., Wang, Y. et al. Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population. Ann Hematol 91, 1065–1072 (2012). https://doi.org/10.1007/s00277-012-1421-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-012-1421-6

Keywords

Search

Navigation